These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pseudohyperkalaemia is a common finding in myeloproliferative disorders that may lead to inappropriate management of patients. Ong YL, Deore R, El-Agnaf M. Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e151-7. PubMed ID: 19016918 [Abstract] [Full Text] [Related]
3. Essential thrombocythemia following polycythemia vera: an unusual sequence. Randi ML, Barbone E, Zerbinati P, Soini B, Rossi C, Girolami A. J Med; 1996 Feb; 27(5-6):363-8. PubMed ID: 9151204 [Abstract] [Full Text] [Related]
4. [Pseudohyperkalemia in the serum in reactive thrombocytosis and thrombocythemia]. Mödder B, Meuthen I. Dtsch Med Wochenschr; 1986 Feb 28; 111(9):329-32. PubMed ID: 3948731 [Abstract] [Full Text] [Related]
5. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH. Platelets; 2004 Mar 28; 15(2):67-84. PubMed ID: 15154599 [Abstract] [Full Text] [Related]
6. [Must we always treat hyperkalaemia?]. Basile C, Manobianca G, Bruno A, Tamma F. G Ital Nefrol; 2013 Mar 28; 30(1):. PubMed ID: 23832444 [Abstract] [Full Text] [Related]
14. Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. Farrukh F, Guglielmelli P, Loscocco GG, Pardanani A, Hanson CA, De Stefano V, Barbui T, Gangat N, Vannucchi AM, Tefferi A. Am J Hematol; 2022 Feb 01; 97(2):E35-E37. PubMed ID: 34822188 [No Abstract] [Full Text] [Related]